Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19

Glascock A, Maguire C, Phan HV, Lydon EC, Schaenman J, Calfee CS, Melamed E, Greenland J, Corry DB, Kheradmand F, Baden LR, Sekaly R, McComsey GA, Haddad EK, Cairns CB, Geng LN, Pulendran B, Fernandez-Sesma A, Simon V, Metcalf JP, Agudelo Higuita NI, Messer WB, Davis MM, Nadeau KC, Kraft M, Bime C, Erle DJ, Atkinson MA, Brakenridge SC, Ehrlich LIR, Montgomery RR, Shaw AC, Hough CL, Hafler DA, Augustine AD, Becker PM, Peters B, Ozonoff A, Hoch A, Kim-Schulze S, Krammer F, Bosinger S, Eckalbar W, Altman MC, Wilson M, Guan L, Maecker H, Steen H; IMPACC Network; Diray-Arce J, Rouphael N, Kleinstein SH, Jayavelu ND, Reed EF, Levy O, Chu VT, Langelier CR. Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19. Nat Microbiol. 2026 Mar 16. doi: 10.1038/s41564-026-02285-8. Epub ahead of print. PMID: 41840216.


Related Posts